AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01292603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-3 or Days 1-5 of cycles 1-6
Study NCT01292603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 1-3 or Days 1-5 of cycles 1-6
Study NCT01292603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
Study NCT01292603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
Study NCT01292603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: 6 cycles of intravenous MabThera
Study NCT04207099 — intervention group
Intervention type: DEVICE
Intervention: MolecuLight i:X Imaging Device
Description: The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
Study NCT03641482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBF
Description: Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
Study NCT03641482 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
Study NCT00846664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Short Arc Banding
Description: Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
Study NCT04390438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrolysis
Description: Needle emplacement with a galvanic electrical current
Study NCT04390438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Needle emplacement without electrical current nor substance
Study NCT03426306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 4DCT-Ventilation
Description: 4DCT-ventilation is an imaging modality that provides superior image quality, reduced cost, and a faster imaging procedure compared to nuclear medicine VQ scans.
Study NCT03137511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
Description: Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
Study NCT05615792 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00857324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~* Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~* In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Study NCT03031691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brontictuzumab
Description: starting dose of 1.5mg/kg administered intravenously (IV)
Study NCT03031691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil
Study NCT03962387 — intervention group
Intervention type: OTHER
Intervention: Not applicable(observational study)
Description: Not applicable(observational study)
Study NCT02041195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Setmelanotide
Study NCT02032134 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Transfusion of Pooled Platelets Cryopreserved In DMSO
Description: Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing
Study NCT03464188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Cornerstone
Description: Project Cornerstone basic elements are:~1. The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician;~2. 6 base telephone/in-person sessions: Sessions cover specific topics (every 1-2 weeks, 20-60 minutes/session; by phone or in-person), followed by monthly follow-up and additional coaching sessions as needed;~3. Regular caregiver distress thermometer screening and problem support and self-care coaching.~4. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions. Project Cornerstone begins within 60 days of a care recipient being diagnosed with advanced cancer and ends 1 year after care recipient death.
Study NCT02041195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04457232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT imaging
Study NCT04457232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 FAPi-46
Description: Given IV
Study NCT04457232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT imaging
Study NCT00808912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg ingested orally 1 hour prior to exercise testing
Study NCT00808912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
Study NCT04086953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones
Study NCT04086953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walk-Time Limit Tes
Description: Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
Study NCT02041195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04086953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Incremental shuttle walk test
Description: Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.
Study NCT04086953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endurance shuttle walk test
Description: Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT.
Study NCT04086953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory Functional Assessment
Description: Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
Study NCT03543202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
Study NCT03543202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration anesthesia
Description: will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia
Study NCT03543202 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous patient controlled analgesia
Description: will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
Study NCT03543202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient controlled analgesia
Description: will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
Study NCT03543202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia
Description: will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
Study NCT00713947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: during one week for the active treatments
Description: during one week for the active treatments placebo during 25 weeks
Study NCT00713947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 6 months at 20 mg
Study NCT01719952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
Study NCT00713947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formula 515
Description: 26 weeks, one tablet per day
Study NCT03364660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute epidural stimulation for cardiovascular stability
Description: Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord. Participants received mapping for cardiovascular stability.
Study NCT03364660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Term Epidural Stimulation for Cardiovascular Stability
Description: Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily.
Study NCT03364660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants undergo approximately 4 months of epidural stimulation for voluntary movement.
Description: Participants undergo approximately 4 months of epidural stimulation for voluntary movement 4-7 days weekly.
Study NCT03364660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Term Epidural Stimulation for Cardiovascular Stability plus Stand Training
Description: Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
Study NCT03364660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants undergo approximately 4 months of epidural stimulation for voluntary movement plus stand training.
Description: Participants undergo approximately 4 months of epidural stimulation for voluntary movement, 4-7 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
Study NCT02490501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SC0806 and rehabilitation
Study NCT02490501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation only
Study NCT02967315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMRI)
Description: There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.~The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast.
Study NCT02967315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous line placement
Description: An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.
Study NCT02967315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: A chest X-ray will be performed for safety reasons to rule out pneumothorax (\< 1% risk) after central line placement.
Study NCT01719952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
Study NCT02395120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard letter
Description: Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
Study NCT02967315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.
Study NCT02967315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: One to two teaspoons of blood will be drawn for basic metabolic panel.
Study NCT02967315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: A urine pregnancy test will be performed in female subjects.
Study NCT02395120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention letter
Description: Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
Study NCT02967315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: 12 lead ECG
Study NCT01532856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, Cyclophosphamide, Dexamethasone
Description: Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
Study NCT01532856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, Dexamethasone
Description: Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
Study NCT01532856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, Melphalan, Prednisone
Description: thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
Study NCT02318446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
Study NCT02318446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saccharine
Description: Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
Study NCT01441765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
Study NCT01441765 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC/RCC fusion vaccine
Description: Vaccination once per cycle on Day 8 of treatment cycles 2-4
Study NCT03577496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
Study NCT02473939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR942 delivered via a Vectura Dry Powder Inhaler
Study NCT02473939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo delivered via a Vectura Dry Powder Inhaler
Study NCT00205023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonohysterography
Description: SHG during surgery for endometrial cancer.
Study NCT04570670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monomethyl fumarate 190 mg
Study NCT04570670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate 240 mg
Study NCT03771560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: subject will take folinic acid daily for 12 weeks
Study NCT02756143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
Study NCT04615403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost
Description: Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
Study NCT03515005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Advisor
Description: Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
Study NCT01104805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Description: Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
Study NCT01104805 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-Usual (TAU)
Description: Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
Study NCT02478424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100.
Study NCT02478424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT02478424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate